Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HER-MES: erenumab versus topiramate in migraine prevention
2018-000943-15Phase 4Completed
- Sponsor
- Novartis
- Start
- Nov 2018
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in migraine comparing Erenumab arm with Topiramate arm (2 arms). Primary endpoint: Discontinuation due to adverse events. Started Nov 2018; status: completed.
02
Drugs
erenumabtopiramate
03
Conditions
migraine
Beyond the preview
Go deeper on 2018-000943-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-000943-15.